Five Tombs of Senior Statesmen Discovered in Egypt

Sarcophaguses that are around 2,500 years old, from the newly discovered burial site near Egypt's Saqqara necropolis, are seen during a presentation in Giza, Egypt November 14, 2020. REUTERS/Mohamed Abd El Ghany/File Photo
Sarcophaguses that are around 2,500 years old, from the newly discovered burial site near Egypt's Saqqara necropolis, are seen during a presentation in Giza, Egypt November 14, 2020. REUTERS/Mohamed Abd El Ghany/File Photo
TT

Five Tombs of Senior Statesmen Discovered in Egypt

Sarcophaguses that are around 2,500 years old, from the newly discovered burial site near Egypt's Saqqara necropolis, are seen during a presentation in Giza, Egypt November 14, 2020. REUTERS/Mohamed Abd El Ghany/File Photo
Sarcophaguses that are around 2,500 years old, from the newly discovered burial site near Egypt's Saqqara necropolis, are seen during a presentation in Giza, Egypt November 14, 2020. REUTERS/Mohamed Abd El Ghany/File Photo

The Egyptian Ministry of Tourism and Antiquities has announced the discovery of five historic cemeteries in the Saqqara region, Giza, (western Cairo) that belong to major statesmen from the Old Kingdom (2686-2181 BC), and the First Intermediate Period (2181-2055 BC), dating to over 4,600 years ago. The ministry organizes a media tour in the site on Saturday to explore the cemeteries.

Minister of Tourism and Antiquities Khaled El Anani visited the discovery site to examine the excavation works led by the Egyptian mission near the King Merenre pyramid in Saqqara. “Five engraved cemeteries containing burials and antiquities from the Old Kingdom and the First Intermediate Period have been discovered in the Saqqara region, which saw many archeological discoveries in the past years,” the minister noted in an official statement.

“This discovery will help rewrite the First Intermediate Period in the Egyptian history because it could provide more information about those who lived and ruled during that period. It was a critical phase in the Egyptian history, it saw the political and economic collapse of the state, the independence of rulers each in his region, and an economic deterioration caused by wasting the state’s resources on building the pyramids in the Old Kingdom, in addition to the scarcity of Nile water and its impact on agriculture,” Dr. Hussein Abdul Bassir, director of the Bibliotheca Alexandrina (BA), told Asharq Al-Awsat.

Saqqara is a part of the Memphis cemetery, located 40 km west of Cairo, and was named after God Seker from the Old Kingdom. The region is an open museum featuring antiquities from different eras of the Egyptian history.
“The first cemetery, burying a senior statesman named Eri, includes a well leading to a burial chamber with engraved walls featuring funerary drawings including sacrifices tables, the palace’s façade, containers of the seven oils, a huge tomb built of limestone, and a collection of engraved pieces that belonged to the cemetery’s owner,” said Mostafa Waziri, secretary-general of the Supreme Council of Antiquities of Egypt and head of the Saqqara mission, in a press statement.

“The archeological mission currently works on cleaning and documenting the discovered cemeteries,” he added.

The second cemetery, a rectangle-shaped well belongs to the wife of a man named ‘Yart’. The third belongs to a man who had many titles including the supervisor of the grand house. The fourth cemetery belongs to a lady, ‘Betty’ who held many titles; it’s a rectangular well located at six meters underground. Built for a man called ‘Heno’, the fifth cemetery is a rectangular well built at seven meters underground. Its owner had many titles including the supervisor of the royal palace and the mayor.

The Pyramid of Djoser, the oldest stone construction in history, is Saqqara’s most known landmark. The Saqqara archeological site includes the cemeteries of kings and senior statesmen from the 1st and 2nd Dynasties, in addition to king pyramids from the 5th and 6th Dynasties including the King Wenis Pyramid, who was the first to engrave his burial chamber with texts to protect himself during his journey in the other world.

The region also features cemeteries of statesmen from the Old Kingdom, the First Intermediate Period, the Middle Kingdom of Egypt (2055-1650 BC), and the New Kingdom (1550-1069 BC) known for its unique architecture and constructions such as the cemetery of King Horemheb (1323-1295 BC).

The region also houses the cemetery of sacred calf Apis, known as Serapeum of Saqqara, which was used from the 18th Dynasty until the Ptolemaic Kingdom. But Saqqara is not only Pharaonic; it includes Coptic landmarks such as the Monastery of Anba Ermia, located to the southeast of King Djoser’s pyramid collection. The Monastery was used until the 10th century AD.

Over the past year, Saqqara witnessed many archeological discoveries including hundreds of colored tombs containing well-preserved mummies of senior statesmen and priests from the 26th Dynasty, selected among the world’s top 10 archeological discoveries in 2020. Two cemeteries of priest Wa Ti, and the supervisor of the royal palace ‘Khoy’, in addition to several cat cemeteries were unearthed last year as well.



Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
TT

Ozempic Hailed as 'Fountain of Youth' that Slows Aging

The is available under the brand names Wegovy and Ozempic (Photo by Reuters)
The is available under the brand names Wegovy and Ozempic (Photo by Reuters)

The anti-obesity drug Ozempic could slow down ageing and has “far-reaching benefits” beyond what was imagined, researchers have suggested.

Multiple studies have found semaglutide (available under the brand names Wegovy and Ozempic) reduced the risk of death in people who were obese or overweight and had cardiovascular disease without diabetes, The Independent reported.

Responding to research published in JACC, the flagship journal of the American College of Cardiology, Professor Harlan M Krumholz from the Yale School of Medicine, said: “Semaglutide, perhaps by improving cardiometabolic health, has far-reaching benefits beyond what we initially imagined.”

He added: “These ground-breaking medications are poised to revolutionise cardiovascular care and could dramatically enhance cardiovascular health.”

Multiple reports also quoted Professor Krumholz saying: “Is it a fountain of youth?”

He said: “I would say if you’re improving someone’s cardiometabolic health substantially, then you are putting them in a position to live longer and better.

“It’s not just avoiding heart attacks. These are health promoters. It wouldn’t surprise me that improving people’s health this way actually slows down the ageing process.”

The studies, presented at the European Society of Cardiology Conference 2024 in London, were produced from the Select trial which studied 17,604 people aged 45 or older who were overweight or obese and had established cardiovascular disease but not diabetes.

They received 2.4 mg of semaglutide or a placebo and were tracked for more than three years.

A total of 833 participants died during the study with 5 percent of the deaths were related to cardiovascular causes and 42 per cent from others.

Infection was the most common cause death beyond cardiovascular, but it occurred at a lower rate in the semaglutide group than the placebo group.

People using the weight-loss drug were just as likely to catch Covid-19, but they were less likely to die from it – 2.6 percent dying among those on semaglutide versus 3.1 per cent on the placebo.

Researchers found women experienced fewer major adverse cardiovascular events, but semaglutide “consistently reduced the risk” of adverse cardiovascular outcomes regardless of sex.

Dr Benjamin Scirica, lead author of one of the studies and a professor of cardiovascular medicine at Harvard Medical School, said: “The robust reduction in non-cardiovascular death, and particularly infections deaths, was surprising and perhaps only detectable because of the Covid-19-related surge in non-cardiovascular deaths.

“These findings reinforce that overweight and obesity increases the risk of death due to many etiologies, which can be modified with potent incretin-based therapies like semaglutide.”

Dr Jeremy Samuel Faust, an emergency medicine physician at Brigham and Women’s Hospital, praised the researchers for adapting the study to look at Covid-19 when the pandemic started.

He said the findings that the weight-loss drug to reduce Covid-19 mortality rates were “akin to a vaccine against the indirect effects of a pathogen.”